“Dose-Modified Lenalidomide Induces Sustained Hematological Response in Patients With Intermediate to High Risk Myelodysplasia”. Mediterranean Journal of Hematology and Infectious Diseases, vol. 2, no. 2, May 2010, p. e2010012, https://doi.org/10.4084/mjhid.2010.012.